Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, announced on October 8, 2026, the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom.

The investment expands the company's global capabilities to support the rapidly growing cell therapy market and strengthens its GMP manufacturing infrastructure for cell therapy applications.

Key Milestone in Global Manufacturing Strategy

The announcement, made from the company's Minneapolis headquarters, positions the Bristol site as the latest milestone in Bio-Techne's broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow.

The facility is fully operational and is already manufacturing GMP-grade small molecules that support customers developing next-generation cell therapies worldwide.

Facility Design and Capabilities

The purpose-built Bristol facility spans 10,000 square feet and features five ISO-8 multifunctional cleanrooms along with two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling.

According to the company, the facility is designed to meet the rigorous standards required for advanced cell therapy manufacturing, enhancing Bio-Techne's ability to provide customers with high-quality GMP materials supported by robust quality systems and reliable global supply.

The new site expands GMP small molecule production capacity and complements the company's recent investments in North America.

Executive Commentary

Kim Kelderman, President and Chief Executive Officer of Bio-Techne, said the company's investment in Bristol demonstrates its commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and bring transformative therapies to patients worldwide.

He noted that as the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale.

Will Geist, President of Bio-Techne's Protein Sciences Segment, said the opening of the Bristol facility represents more than additional manufacturing capacity.

According to Geist, it strengthens the company's ability to serve as a long-term partner for cell therapy innovators by providing the quality, scale, and global support necessary to navigate the journey from discovery to commercial supply.

An Integrated Global Manufacturing Network

The Bristol expansion builds on Bio-Techne's existing manufacturing footprint, which includes recombinant protein manufacturing operations in Minneapolis, Minnesota, and extensive GMP capabilities in St. Paul.

The company also holds a strategic relationship with Wilson Wolf Corporation, a manufacturer of cell culture devices including the widely adopted G-Rex platform.

Together, these operations allow Bio-Techne to offer an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support.

Collectively, the company states, these capabilities help customers transition seamlessly from research through clinical development and commercial production, with combined capabilities across Bristol, St. Paul, and Minneapolis supporting customers from discovery through commercial manufacturing.

Addressing Industry Challenges

Bio-Techne framed the investment as a response to one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.

According to the company, cell therapy developers face mounting pressure to reduce variability, standardize manufacturing processes, and scale production efficiently while meeting evolving regulatory expectations.

The company addresses these challenges through high-quality GMP materials, scalable manufacturing solutions, and analytical technologies designed to improve consistency and accelerate development timelines.

Bio-Techne also noted that recent industry discussions have increasingly highlighted manufacturing scalability as a critical factor in enabling broader patient access to advanced therapies, reinforcing the importance of investments such as the Bristol expansion.

About Bio-Techne

Bio-Techne Corporation is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities.

The company provides high-quality reagents, analytical instruments, and precision diagnostics, with a portfolio organized into three customer-focused brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, reflecting the scientific journey from discovery to translational research to clinical decision-making.

Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over USD 1.2 billion in net sales, and its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

Stay Ahead of the United Kingdom's Shifting Chemical Project Landscape

The United Kingdom chemical sector is undergoing a profound transformation, with sustainability mandates, feedstock shifts, and decarbonization targets reshaping where and how new capacity gets built. Missing a single tender notice or contract award could mean losing your competitive edge in this fast-moving market.

Tracking project developments, regulatory frameworks, and plant types across the United Kingdom is a full-time job, one that most teams simply don't have the bandwidth for. That's where structured, real-time intelligence becomes invaluable.

The Global Project Tracking (GPT) platform by Blackridge Research gives you a consolidated view of chemical sector projects across Europe, from early-stage announcements through final commissioning, so your team can act on opportunities before competitors even hear about them.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Book a Free Demo today and see how the Global Project Tracking (GPT) platform by Blackridge Research can sharpen your strategy in the United Kingdom's chemical market.